Search research articles
Contact Us
Filters
Showing results (431-440 of 459) with videos related to
Page
of 46
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Connor J Kinslow, Ali I Rae, Kekoa Taparra, et al.
Neurology
|
October 22, 2008
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
S A Grimm, C A McCannel, A M P Omuro, et al.
Neuro-Oncology
|
April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
Lakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2012
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study
Y-H Wang, M Trucksis, J J McElwee, et al.
Neuro-Oncology
|
November 5, 2025
Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma
Antonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, et al.
Practical Radiation Oncology
|
March 9, 2016
Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma
Tony J C Wang, Cheng-Chia Wu, Ashish Jani, et al.
Nature Medicine
|
February 12, 2019
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao, Andrew X Chen, Robyn D Gartrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2025
Dual Immune Check Point Blockade in <i>MGMT</i>-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial
Andrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Nature Medicine
|
April 19, 2019
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao, Andrew X Chen, Robyn D Gartrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2024
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Fabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, et al.
Page
of 46
Search research articles
Search
Showing results (431-440 of 459) with videos related to
Sort By:
Page
of 46
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Connor J Kinslow, Ali I Rae, Kekoa Taparra, et al.
Neurology
|
October 22, 2008
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report
S A Grimm, C A McCannel, A M P Omuro, et al.
Neuro-Oncology
|
April 29, 2017
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria
Lakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, et al.
Clinical Pharmacology and Therapeutics
|
June 7, 2012
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study
Y-H Wang, M Trucksis, J J McElwee, et al.
Neuro-Oncology
|
November 5, 2025
Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma
Antonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, et al.
Practical Radiation Oncology
|
March 9, 2016
Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma
Tony J C Wang, Cheng-Chia Wu, Ashish Jani, et al.
Nature Medicine
|
February 12, 2019
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao, Andrew X Chen, Robyn D Gartrell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2025
Dual Immune Check Point Blockade in <i>MGMT</i>-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial
Andrew B Lassman, Mei-Yin C Polley, Fabio M Iwamoto, et al.
Nature Medicine
|
April 19, 2019
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao, Andrew X Chen, Robyn D Gartrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2024
Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Fabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, et al.
Page
of 46